

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM504308

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Sancilio Pharmaceuticals Company, Inc.		07/26/2018	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Michelle Biopharma, Inc.		
<b>Street Address:</b>	2129 N. Congress Avenue		
<b>City:</b>	Riviera Beach		
<b>State/Country:</b>	FLORIDA		
<b>Postal Code:</b>	33404		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	5314532	SANCILIO PHARMACEUTICALS COMPANY, INC.	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	9195737460		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	919-573-7439		
<b>Email:</b>	USTRademark@nexsenpruet.com		
<b>Correspondent Name:</b>	E. Eric Mills		
<b>Address Line 1:</b>	4141 Parklake Avenue		
<b>Address Line 2:</b>	Suite 200		
<b>Address Line 4:</b>	Raleigh, NORTH CAROLINA 27612		
<b>NAME OF SUBMITTER:</b>	E. Eric Mills		
<b>SIGNATURE:</b>	/E. Eric Mills/		
<b>DATE SIGNED:</b>	01/03/2019		
<b>Total Attachments: 19</b>			
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page1.tif			
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page2.tif			
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page3.tif			
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page4.tif			

CH \$40.00 5314532

source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page5.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page6.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page7.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page8.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page9.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page10.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page11.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page12.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page13.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page14.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page15.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page16.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page17.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page18.tif  
source=Intellectual Property Assignment Agreement (Michelle) EXECUTED#page19.tif

## **INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT**

**THIS INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT** (this “Assignment”), effective as of August 8, 2018, is by and between (i) Sancilio Pharmaceuticals Company, Inc., a Delaware corporation, (ii) Sancilio & Company, Inc., a Delaware corporation, and (iii) Blue Palm Advertising Agency, LLC, a Florida limited liability company (collectively, the “Assignors”), and Micelle BioPharma, Inc., a Delaware corporation (“Assignee”). Assignor and Assignee are each a “Party” hereto and are collectively referred to herein as the “Parties”. Unless otherwise defined herein, all capitalized terms used herein shall have the meanings ascribed to such terms in the Purchase Agreement (as defined below).

### **WITNESSETH:**

WHEREAS, pursuant to the terms and subject to the conditions of the Asset Purchase Agreement, dated July 19, 2018 (the “Purchase Agreement”), between the Assignee and the Assignors, the Assignors have agreed to sell to the Assignee, and the Assignee has agreed to purchase from the Assignors, among other things, the Purchased Assets; and

WHEREAS, pursuant to the Purchase Agreement, the Assignors desire to sell, assign, convey, deliver and transfer the entire right, title and interest in, to and under all Company Owned Intellectual Property, including (i) all Seller Names and Marks and (ii) Patents, Copyrights and Trademarks and other Intellectual Property set forth on Schedule A hereto (collectively, the “Acquired Intellectual Property”); to the Assignee and the Assignee desires to acquire the entire right, title and interest in, to and under such Acquired Intellectual Property.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, and as more fully set forth in the Purchase Agreement and subject to the terms and conditions therein, the Parties, intending to be legally bound, hereby agree as follows:

1. The Assignors hereby irrevocably sell, assign, convey, deliver and transfer to the Assignee the entire right, title and interest in, to and under (i) the Acquired Intellectual Property, together with all goodwill associated therewith, in each case to be held and enjoyed by the Assignee for its own use and enjoyment as fully and entirely as the same would have been held and enjoyed by the Assignors if this assignment and sale had not been made, including the right to claim priority under the International Convention for the Protection of Industrial Property and under any other international arrangement to which the United States of America is or hereafter becomes a signatory (but not, for the avoidance of doubt, any Excluded Liability), (ii) all rights to sue, claim and recover for past, present and future infringement, misappropriation, dilution or other violation of any Acquired Intellectual Property, and (iii) all income, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing.

2. Concurrent with the execution of this Assignment, the Assignors shall transfer any and all domain names and social media accounts included in the Acquired Intellectual Property from the Assignors’ accounts to the Assignee’s account (such that the Assignee will be

listed as the registrant and/or owner of such domain names and social media accounts in the applicable registrar) and shall deliver to the Assignee all necessary Auth-Info codes and all other required passwords necessary to unlock and control such domain names and social media accounts.

3. Subject to the other express provisions of this Assignment and the Purchase Agreement, upon the request of either the Assignee, on the one hand, or the Assignors, on the other hand, the other party will execute and deliver such other documents, instruments and agreements as the requesting party may reasonably require for the purpose of carrying out the intent of this Assignment and the Purchase Agreement and the transactions contemplated by this Assignment and the Purchase Agreement.

4. Assignors hereby authorize and request the officials of the United States Copyright Office and the United States Patent and Trademark Office, and the corresponding entities or agencies in any applicable foreign jurisdiction, to record and register Assignee as assignee and owner of the entire right, title and interest in, to and under the Acquired Intellectual Property.

5. Section 10.12 of the Purchase Agreement is hereby incorporated by reference into this Agreement and shall apply as if fully set forth herein *mutatis mutandis*.

6. This Assignment is binding upon, and inures to the benefit of, the parties hereto and their respective legal representatives, successors and assigns. No waiver, modification or change of any provision of this Assignment shall be valid unless in writing and signed by the Party against whom such claimed waiver, modification or change is sought to be enforced.

7. The Parties may execute this Assignment in multiple counterparts, each of which constitutes an original as against the Party that signed it, and all of which together constitute one agreement. This Assignment is effective upon delivery of one executed counterpart from one Party to the other Party. The signatures of all Parties need not appear on the same counterpart. The delivery of signed counterparts by facsimile or email transmission that includes a copy of the sending Party's signature(s) is as effective as signing and delivering the counterpart in person.

[Signature Pages Follow]

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed on the date first above written.

AS ASSIGNORS:

SANCILIO PHARMACEUTICALS  
COMPANY, INC.

By: [Signature]  
Name: Geoffrey Glass  
Title: Chief Executive Officer

SANCILIO & COMPANY, INC.


By: [Signature]  
Name: Geoffrey Glass  
Title: Chief Executive Officer

BLUE PALM ADVERTISING AGENCY, LLC

By: [Signature]  
Name: Geoffrey Glass  
Title: Chief Executive Officer

STATE OF FLORIDA     )  
                                          ) ss  
COUNTY OF PALM BEACH )

On the 26<sup>th</sup> day of July, 2018 before me personally came Geoffrey Glass, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as C.E.O. of SPCI, SCL, PBAAT, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

 Elizabeth Whitney Salazar  
NOTARY PUBLIC  
STATE OF FLORIDA  
Comm# GG156393  
Expires 11/30/2021  
(PLACE STAMP AND SEAL ABOVE)

[Signature]  
Notary Public

*[Signature Page to Intellectual Property Assignment]*



**SCHEDULE A**

**ACQUIRED INTELLECTUAL PROPERTY**

**PATENTS**

Green = Issued  
 Red = Abandoned/Expired  
 White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.PR	Omega-3 Compositions and Methods for Enhanced Systemic Absorption ("SC401B.PR")	United States (US)		61/618,161
SC401B.PCT	Omega-3 Fatty Acid Ester Compositions ("SC401B.PCT")	International (PCT)		US2013/030211
	Pharmaceutical Compositions ("EO Provisional")	United States (US)		61/775,865
	Pharmaceutical Composition For The Controlled Release Of Calcium	United States (US)		
	Pharmaceutical Composition With Reduced Food Effect	United States (US)		
	Soft Gelatin Capsule Drying Process	United States (US)		
	Formulators for Solubilizing Hormones	United States (US)		61/871,415
	Drug Delivery Systems Containing Monoglycerides	United States (US)		61/946,924
SC440.PR	Formulators for Solubilizing Hormones ("SC440.PR")	United States (US)		62/026,717
	Oral Liquid Compositions	United States (US)		09/354,982
SC401B.US1	Omega-3 Fatty Acid Ester Compositions ("SC401B.US1")	United States (US)		14/456,731
SC401B.US2	Omega-3 Fatty Acid Ester Compositions ("SC401B.US2")	United States (US)		14/456,750
SC401B.DZ	Omega-3 Fatty Acid Ester Compositions ("SC401B.DZ")	Algeria (DZ)		140557



Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.AU	Omega-3 Fatty Acid Ester Compositions ("SC401B.AU")	Australia (AU)	Spusser (P124697)	2013240427
SC401B.BR	Omega-3 Fatty Acid Ester Compositions ("SC401B.BR")	Brazil (BR)		BR1120140242313
SC401B.CA	Omega-3 Fatty Acid Ester Compositions ("SC401B.CA")	Canada (CA)		2,867,168
SC401B.CN	Omega-3 Fatty Acid Ester Compositions ("SC401B.CN")	China (CN)		201380027275.8
SC401B.CO	Omega-3 Fatty Acid Ester Compositions ("SC401B.CO")	Colombia (CO)		14-240867
SC401B.EG	Omega-3 Fatty Acid Ester Compositions ("SC401B.EG")	Egypt (EG)		1471/2014
SC401B.EP	Omega-3 Fatty Acid Ester Compositions ("SC401B.EP")	Europe (EP)		13712624.9
SC401B.IN	Omega-3 Fatty Acid Ester Compositions ("SC401B.IN")	India (IN)		8449/DELNP/2014
SC401B.IL	Omega-3 Fatty Acid Ester Compositions ("SC401B.IL")	Israel (IL)	Reinhold Cohn & Partners (2309898-YF)	234814
SC401B.JP	Omega-3 Fatty Acid Ester Compositions ("SC401B.JP")	Japan (JP)		2015-503245
SC401B.MY	Omega-3 Fatty Acid Ester Compositions ("SC401B.MY")	Malaysia (MY)		PI 2014002698
SC401B.MX	Omega-3 Fatty Acid Ester Compositions ("SC401B.MX")	Mexico (MX)		MX/a/2014/011596
SC401B.RU	Omega-3 Fatty Acid Ester Compositions ("SC401B.RU")	Russia (RU)		2014141406

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.KR	Omega-3 Fatty Acid Ester Compositions ("SC401B.KR")	South Korea (KR)		2014-7029132
SC401B.AE	Omega-3 Fatty Acid Ester Compositions ("SC401B.AE")	United Arab Emirates (AE)		P1050/14
SC403.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Fat Malabsorption Syndromes ("SC403.PR")	United States (US)		62/062,638
SC404.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Primary Sclerosing Cholangitis ("SC404.PR")	United States (US)		62/062,643
SC410.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis ("SC410.PR")	United States (US)		62/062,646
SC430.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Neurodegenerative Diseases ("SC430.PR")	United States (US)		62/062,651
SC411.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Sickle Cell Disease ("SC411.PR")	United States (US)		62/062,652

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC412.PR	Omega-3 Fatty Acid Ester Compositions and Their Use in the Treatment of Macular Degeneration (SC412.PR)	United States (US)		62,062,694
SC401B.CIP.1A	Omega-3 Fatty Acid Ester Compositions (SC401B.CIP.1A)	United States (US)		14,578,709
SC401B.CIP.1B	Omega-3 Fatty Acid Ester Compositions (SC401B.CIP.1B)	United States (US)		14,578,692
SC401B.CIP.1C	Omega-3 Fatty Acid Ester Compositions (SC401B.CIP.1C)	United States (US)		14,578,697
SC402.CIP.1	Omega-3 Fatty Acid Ester Compositions (SC402.CIP.1)	United States (US)		15,058,228
SC401B.HK	Omega-3 Fatty Acid Ester Compositions (SC401B.HK)	Hong Kong (HK)		15105834.2
SC401B.US3	STABLE MICELLES OF FATTY ACID ESTERS (SC401B.US3)	United States (US)		14,808,935
SC401B.US4	STABLE MICELLES OF MIXED FATTY ACIDS (SC401B.US4)	United States (US)		14,808,777
SC401B.US5	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE (SC401B.US5)	United States (US)		14,808,909
SC401B.US6	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASES (SC401B.US6)	United States (US)		14,808,947

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.US7	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF MACULAR DEGENERATION AND PRIMARY SCLEROSING CHOLANGITIS ("SC401B.US7")	United States (US)		14/808,866
SC401B.US8	STABLE MICELLES OF FATTY ACID ESTERS FOR THE TREATMENT OF DISEASE STATES ("SC401B.US8")	United States (US)		14/808,871
SC401B.US9	FUNCTIONAL FOODS AND KITS CONTAINING STABLE MICELLES OF FATTY ACID ESTERS ("SC401B.US9")	United States (US)		14/808,876
SC400.PR	ENHANCED TREATMENT OF DISEASE STATES UTILIZING ADVANCED LIPID TECHNOLOGIES	United States (US)		62/207,072
SC400E	SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES ("SC400E")	International (PCT)		PCT/US2015/054933
SC401B.CIP.1A.CIP	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.1A.CIP")	United States (US)		15/132,278
SC401B.CIP.1B.CIP	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.1B.CIP")	United States (US)		15/134,419
SC401B.CIP.1C.CIP	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.1C.CIP")	United States (US)		15/134,417

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.EP.DIV	Omega-3 Fatty Acid Ester Compositions ("SC401B.EP.DIV")	Europe (EP)		16165946.1
SC400E_US	SELF-MICELLIZING FATTY ACIDS AND FATTY ACID ESTER COMPOSITIONS AND THEIR USE IN THE TREATMENT OF DISEASE STATES ("SC400E_US")	United States (US)		15/180,430
SC_DES	Mod for a Medical Dosage Form	United States (US)	N/A	29/575,454
SC401B.IL.DIV	Omega-3 Fatty Acid Ester Compositions ("SC401B.IL.DIV")	Israel (IL)	Reinhold Cohn & Partners (2462403-YF)	249821
SC400E.ZA	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.ZA)	South Africa (ZA)	Spoor & Fisher (PA167379/Z)	2017/02385
SC400E.CA	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.CA)	Canada (CA)	Ostler (PCA29385)	2,963,952
SC400E.CL	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.CL)	Chile (CL)	Balder IP Law (P170836CL)	2017-00867
SC400E.EP	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.EP)	Europe (EP)	HGF Limited (P241710EP/KLT/JG)	157848771

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC400E.MX	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.MX)	Mexico (MX)	Vadillo & King (6566)	MX/A/2017/004324
SC400E.NG	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.NG)	Nigeria (NG)	Spoor & Fisher (PA512667/NG/MLG)	Not yet issued
SC400E.OM	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.OM)	Oman (OM)	Saba & Company (OM/T/43782/998/17)	OM/P/2017/00101
SC400E.AP	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.AP)	ARIPO (AP)	Spoor & Fisher (PA512667/AP/MLG)	F/P/2017/200
SC400E.BR	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.BR)	Brazil (BR)	Daniel Legal & IP Strategy (173.759-7)	BR1120170074281
SC400E.IN	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.IN)	India (IN)	Kan & Krishme (KC20170311062)	2.01717E+11
SC400E.SA	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States (SC400E.SA)	Saudi Arabia (SA)	Saba & Company (SA/T/43782/8097/17)	517381254

Green = Issued

Red = Abandoned/Expired

White = In Prosecution

SCI Ref. No.	Title	Country	Foreign Associate (Ref. #)	Patent Application Serial No.
SC401B.CIP.1C.CIP.CON	Omega-3 Fatty Acid Ester Compositions ("SC401B.CIP.CON")	United States (US)	N/A	15/590,420
SC400E_US.CON	Self-Micellizing Fatty Acids and Fatty Acid Ester Compositions and Their Use in the Treatment of Disease States ("SC400E_US.CON")	United States (US)	N/A	15/605972
SC411.PR2	Sickle Cell Disease Treatment Utilizing Omega-3 Fatty Acids	United States (US)	N/A	62/563433

# TRADEMARKS

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
PREPARE	United States (US)	Sancilio & Company, Inc.	N/A	858390897	1/24/2013		
LUDENT	United States (US)	Sancilio & Company, Inc.	N/A	77865700	11/5/2009	3869394	IC 065: Chewable fluoride tablet for the prevention of dental caries.
MVC	United States (US)	Sancilio & Company, Inc.	N/A	77778745	7/10/2009	3801019	Class 5: Chewable multivitamin tablets.
ICEBOLTZ	United States (US)	Sancilio & Company, LLC (original, but then assigned to other party)	N/A	77067114	12/19/2006	3412283	Class 3: Breath freshener Class 30: Candy; candy mints.
MYRISTANATE	United States (US)	Sancilio & Company, Inc.	N/A	77262975	8/23/2007	3554899	Class 1: Naturally occurring combination of myristic acid and myristoleic acid used as an ingredient in the manufacture of dietary and nutritional supplements Class 5: Naturally occurring combination of myristic acid and myristoleic acid for use as a component of dietary and nutritional supplements and as a dietary and nutritional supplement.

TRADEMARK



Green = Issued

Red = Abandoned/Exp


White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
DEVELOPING GOOD SCIENCE INTO GREAT MEDICINE	United States (US)	Sancilio & Company, Inc.	N/A	86708015	7/29/2015	4870877	IC 065: Dietary and nutritional supplements; Dietary supplements for human consumption; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Multi-vitamin preparations; Vitamin supplements
ADVANCED LIPID TECHNOLOGIES	United States (US)	Sancilio & Company, Inc.	N/A	86628758	5/13/2015	5215442	IC 065: Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for delivery of lipid-based pharmaceutical preparations.

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
SANCILIO PHARMACEUTICALS COMPANY, INC.	US	Sancilio Pharmaceuticals Company, Inc.	N/A	86735298	8/24/2015	5314532	Class 5: Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals, drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals, pharmaceutical preparations for the prevention of various human disorders, namely, sickle cell disease, short bowel syndrome, hyperglycemia, and inflammatory disorders; pharmaceutical preparations for the treatment of various human disorders, namely, sickle cell disease, short bowel syndrome, hyperglycemia, and inflammatory disorders; pharmaceutical preparations for the treatment of various human disorders, namely, sickle cell disease, short bowel syndrome, hyperglycemia, and inflammatory disorders.
 Sancilio & Company, Inc. Proprietary Good Name Use, Good Services	United States (US)	Sancilio & Company, Inc.	N/A	86694356	7/15/2015	4895811	IC 005: Dietary and nutritional supplements; Dietary supplements for human consumption; Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Multi-vitamin preparations; Vitamin supplements.

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
ALT	United States (US)	Sancilio & Company, Inc.	N/A	86628786	5/13/2015	5032780	IC 005: Drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Pharmaceutical preparations for delivery of lipid-based pharmaceutical preparations
ETHYL CERVOONATE	United States (US)	Sancilio & Company, Inc.	N/A	87110717	7/20/2016		IC 005: Pharmaceutical preparations for the treatment and prevention of sickle cell disease, short bowel syndrome, hypertiglyceridemia, and inflammatory disorders
ABSORVIA	United States (US)	Sancilio & Company, Inc.	N/A	87139990	8/16/2016		IC 005: prenatal vitamins; nutraceuticals for use as a dietary supplement
CALACTIVE	United States (US)	Sancilio & Company, Inc.	N/A	87181487	9/23/2016		IC 005: Dietary supplements; Dietary supplements consisting primarily of calcium and omega-3.
ADVANCED LIPID TECHNOLOGIES	United States (US)	Sancilio & Company, Inc.	N/A	87101390	7/12/2016	5168729	IC 040: Contract manufacturing in the field of drug delivery agents; IC 042: Pharmaceutical research and development; Scientific research and development
OLERALIFE	United States (US)	Sancilio & Company, Inc.	N/A	87294112	11/11/2016		IC 005: Dietary supplements
ALL-IN-ONE	United States (US)	Sancilio & Company, Inc.	N/A	87503170	6/23/2017		IC 005: Nutritional supplements; Dietary and nutritional supplements containing calcium, omega-3 and DS

TRADE MARK

REEL: 006516 FRAME: 0377

Green = Issued

Red = Abandoned/Exp

White = In Prosecution

Trademark	Country	Owner	Foreign Associate and FA Ref. #	Trademark Application Serial No.	Filing Date	Trademark Reg. No	International Class (IC) and Description
SANCILIO PHARMACEUTICALS	China (CN)	Sancilio Pharmaceuticals Company, Inc.	S&F	25543609	7/27/2017		IC 005: Dietary and nutritional supplements; Dietary supplements for human consumption; Drug delivery agents in the form of capsules; provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Multi-vitamin preparations; Vitamin supplements.
ALTEMIA	United States (US)	Sancilio & Company, Inc.	N/A	87/523,640	7/11/2017		IC 005: Pharmaceutical preparations for treatment of lipid imbalances, including sickle cell disease
MYLEK3	United States (US)	Sancilio & Company, Inc.	N/A	87/523,681	7/11/2017	5422269	IC 005: Dietary and nutritional supplements containing omega-3, vitamin D, and calcium; Dietary and nutritional supplements
ALT	Europe (EU)	Sancilio & Company, Inc.					
ADVANCED LIPID TECHNOLOGIES	Europe (EU)	Sancilio & Company, Inc.					

**COPYRIGHTS**

None.

25190200.1